CAMP4 Therapeutics (NASDAQ:CAMP) Raised to "Hold" at Zacks Research

Key Points

• Zacks Research upgraded CAMP4 Therapeutics from “strong sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $9.56.
• The stock opened at $4.90, with a market capitalization of approximately $307.5 million. The company reported a quarterly loss of $0.58 per share, missing estimates by $0.34, on revenue of $1.78 million.
• Insiders purchased 36,031 shares worth approximately $59,451 over the past three months, and insiders collectively own 21.69% of the company.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) was upgraded by investment analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Monday,Zacks.com reports.

Several other brokerages have also weighed in on CAMP. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a "buy" rating in a report on Wednesday, June 10th. Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Weiss Ratings raised CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $9.56.

CAMP4 Therapeutics Stock Down 2.0%

Shares of NASDAQ:CAMP opened at $4.90 on Monday. CAMP4 Therapeutics has a 52-week low of $1.41 and a 52-week high of $7.75. The company has a 50 day moving average of $4.10 and a two-hundred day moving average of $4.32. The company has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, equities analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Activity

In other CAMP4 Therapeutics news, Director Richard A. Young acquired 16,378 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This represents a 9.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased 36,031 shares of company stock worth $59,451 in the last three months. Insiders own 21.69% of the company's stock.

Institutional Trading of CAMP4 Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. bought a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $70,000. State Street Corp boosted its holdings in shares of CAMP4 Therapeutics by 52.7% in the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider's stock valued at $243,000 after acquiring an additional 13,700 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $86,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter worth approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source